Skip to main content
Clinical Trials/NCT02241408
NCT02241408
Unknown
Not Applicable

Autologous Adipose Stromal Vascular Fraction Outcomes in Osteoarthritis Research Study

StemGenex1 site in 1 country100 target enrollmentSeptember 2014
ConditionsOsteoarthritis

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Osteoarthritis
Sponsor
StemGenex
Enrollment
100
Locations
1
Primary Endpoint
Change from Baseline in Overall Knee Assessment Over the Course of a 12 Month Period as Measured by the Knee Injury and Osteoarthritis Outcome Score (KOOS LK 1.0)
Last Updated
7 years ago

Overview

Brief Summary

The purpose of this study is to determine the impact that treatment with a cellular concentrate derived from an individual's own fat, known as the stromal vascular fraction (SVF), has on joint pain and functionality in people with Osteoarthritis (OA). SVF contains components with "regenerative" properties, including stem cells that have shown promise for ameliorating specific disease conditions. This study is designed to evaluate joint pain and functionality changes in individuals with OA for up to 12 months following SVF treatment.

Registry
clinicaltrials.gov
Start Date
September 2014
End Date
September 2019
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
StemGenex
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Fluent in English
  • Over the age of 18
  • Diagnosed with OA of the knee and/or hip
  • Scheduled for intravenous and intra-articular administrations of autologous SVF
  • Capable of understanding and willing to sign informed consent
  • Willing and able to complete brief phone interviews
  • Willing and able to complete online surveys

Exclusion Criteria

  • Co-morbidity with an autoimmune disorder
  • Pregnant, may become pregnant, or breastfeeding
  • Subjects for which baseline data is not available

Outcomes

Primary Outcomes

Change from Baseline in Overall Knee Assessment Over the Course of a 12 Month Period as Measured by the Knee Injury and Osteoarthritis Outcome Score (KOOS LK 1.0)

Time Frame: Baseline, 12 months

The change from baseline over the course of 12 months using participants' assessment of their knee and associated problems. Mean scores will be used for baseline (day 0) and all interviews up to month 12 (months 1, 3, 6, and 12). Answer options are graded on a 5 point Likert scale and each question gets a score from 0 to 4.

Change from Baseline in Overall Hip Assessment Over the Course of a 12 Month Period as Measured by the Hip Dysfunction and Osteoarthritis Outcome Score (HOOS LK 2.0)

Time Frame: Baseline, 12 months

The change from baseline over the course of 12 months using participants' assessment of their hip and associated problems. Mean scores will be used for baseline (day 0) and all interviews up to month 12 (months 1, 3, 6, and 12). Answer options are graded on a 5 point Likert scale and each question gets a score from 0 to 4.

Secondary Outcomes

  • Change from Baseline in Knee Pain at Month 12 as Measured by Participants Using the Knee Injury and Osteoarthritis Outcome Score (KOOS LK 1.0) The Pain Subscale(Baseline, Month 12)
  • Change from Baseline in Function in Daily Living (ADL) at Month 12 as Measured by Participants Using the Hip Dysfunction and Osteoarthritis Outcome Score (HOOS LK 2.0) The ADL Subscale(Baseline, Month 12)
  • Change from Baseline in Function in Sport and Recreation at Month 12 as Measured by Participants Using the Hip Dysfunction and Osteoarthritis Outcome Score (HOOS LK 2.0) The Sport/Rec Subscale(Baseline, Month 12)
  • Change from Baseline in Other Hip Symptoms at Month 12 as Measured by Participants Using the Hip Dysfunction and Osteoarthritis Outcome Score (HOOS LK 2.0) The Other Symptoms Subscale(Baseline, Month 12)
  • Change from Baseline in Other Knee Symptoms at Month 12 as Measured by Participants Using the Knee Injury and Osteoarthritis Outcome Score (KOOS LK 1.0) The Other Symptoms Subscale(Baseline, Month 12)
  • Change from Baseline in Function in Daily Living (ADL) at Month 12 as Measured by Participants Using the Knee Injury and Osteoarthritis Outcome Score (KOOS LK 1.0) The ADL Subscale(Baseline, Month 12)
  • Change from Baseline in Hip Related Quality of Life (QOL) at Month 12 as Measured by Participants Using the Hip Dysfunction and Osteoarthritis Outcome Score (HOOS LK 2.0) The QOL Subscale(Baseline, Month 12)
  • Change from Baseline in Function in Sport and Recreation at Month 12 as Measured by Participants Using the Knee Injury and Osteoarthritis Outcome Score (KOOS LK 1.0) The Sport/Rec Subscale(Baseline, Month 12)
  • Change from Baseline in Knee Related Quality of Life (QOL) at Month 12 as Measured by Participants Using the Knee Injury and Osteoarthritis Outcome Score (KOOS LK 1.0) The Knee Related Quality of Life Subscale(Baseline, Month 12)
  • Change from Baseline in Hip Pain at Month 12 as Measured by Participants Using the Hip Dysfunction and Osteoarthritis Outcome Score (HOOS LK 2.0) The Pain Subscale(Baseline, Month 12)

Study Sites (1)

Loading locations...

Similar Trials